Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 6/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.30 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.30 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.30 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624986 | 0.89 | ALOX5AP (0.38) | FEN1ALOX5APGAAHTTALDH1A1 | |
| SCHEMBL16618084 | 0.87 | FEN1 (0.44) | FEN1ALOX5APGAAHTTPOLB | |
| SCHEMBL16617075 | 0.83 | ALOX5AP (0.39) | FEN1ALOX5APGAAHTTPOLB | |
| SCHEMBL18622659 | 0.81 | FEN1 (0.41) | FEN1ALOX5APGAAHTTALDH1A1 | |
| SCHEMBL16624992 | 0.80 | ALOX5AP (0.38) | FEN1ALOX5APGAAHTTMET | |
| SCHEMBL16624984 | 0.79 | FEN1 (0.40) | FEN1ALOX5APGAAHTT | |
| SCHEMBL16624994 | 0.79 | KDM4E (0.34) | FEN1ALOX5AP | |
| SCHEMBL5123913 | 0.77 | HTT (0.38) | FEN1ALOX5APGAAHTTALDH1A1 | |
| SCHEMBL19510741 | 0.75 | MAP4K4 (0.49) | FEN1ALOX5APGAAHTTPOLB | |
| SCHEMBL5397064 | 0.74 | MET (0.39) | FEN1ALOX5APMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-9533959-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533959-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160159749-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
| US-20160159749-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
| US-20160159749-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
| US-9296727-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296727-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296727-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150099875-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099875-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099875-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | FEN1 305/4885ALOX5AP 2322/4885GAA 2898/4885 |
| US-20160159749-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | FEN1 305/4885ALOX5AP 2322/4885GAA 2898/4885 |
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | TYMS, UMPS, DPYD | FEN1 305/4885ALOX5AP 2322/4885GAA 2898/4885 |
| US-20150099875-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | FEN1 305/4885ALOX5AP 2322/4885GAA 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.